Navigation Links
SemBioSys provides update on insulin program

CALGARY, April 1 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, provides an update on its proprietary plant-produced recombinant human insulin program. In December 2008, SemBioSys announced that MannKind Corporation purchased a non-refundable option to license rights to SemBioSys' proprietary plant-produced recombinant human insulin to be used primarily for AFRESA(TM), MannKind's ultra-rapid acting insulin product. At the time the option was taken, MannKind had completed diligence related to the SemBioSys insulin program and final written agreements had been prepared for execution, were the option to be exercised. In March 2009, MannKind announced that it had entered into agreements with Pfizer Inc. "to purchase Pfizer's insulin facility at Industriepark Hoechst, Frankfurt am Main, Germany and assets related to the production of bulk insulin, including the relevant real property rights, the production equipment, a quantity of bulk insulin and a license to manufacture bulk insulin for use in pulmonary delivery." The option period for SemBioSys' agreement with MannKind expired yesterday without action and SemBioSys is now free to execute agreements relating to its insulin program with other parties.

Also in March 2009, SemBioSys reported results from the Phase I/II trial of its recombinant human insulin (SBS-1000) in human volunteers. SBS-1000 was shown to be bioequivalent to Eli Lilly's Humulin(R) R, a widely-used human insulin in North America.

"Based on prior discussions with third parties, we believe that our recent clinical trial results position us well to continue and expand our partnership discussions," said James Szarko, Chief Executive Officer of SemBioSys. "While the MannKind option was attractive from a timing point of view, and provided a valuable cash infusion, additional partnering options may be open to us now that we have positive clinical data for plant-made insulin."

About SemBioSys

Calgary, Alberta-based SemBioSys is a world leader in manufacturing high-value proteins and oils in plant seeds. With its unique, proprietary platform, SemBioSys provides partners with product enablement, exceptionally low cost and unprecedented scalability. The Company applies this platform with high selectivity to opportunities where it has a unique competitive advantage. Since its inception, SemBioSys has produced more than 50 non-native proteins and oils using its patented seed technology, demonstrating applicability across a broad range of industries such as pharmaceuticals, personal care and industrial products. The Company's current pharmaceutical development programs include insulin (SBS-1000, regulated as a biosimilar in Europe) and Apo AIMilano, a next-generation cardiovascular therapy. SemBioSys is listed on the Toronto Stock Exchange under the ticker SBS. More information is available at

This press release contains certain forward-looking statements, including, without limitation, statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and other similar expressions which constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements reflect the Company's current expectation and assumptions, and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, changing market conditions, the successful and timely completion of clinical studies, the establishment of corporate alliances, the impact of competitive products and pricing, new product development, uncertainties related to the regulatory approval process and other risks detailed from time-to-time in the Company's ongoing filings with the Canadian securities regulatory authorities which filings can be found at Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable Canadian securities laws.

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
2. SemBioSys announces senior management changes
3. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
4. SemBioSys begins phase I/II trial of insulin produced in plant seeds
5. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
6. SemBioSys announces second quarter 2008 financial and operational results
7. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
8. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
9. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
10. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
11. SemBioSys announces first quarter 2008 financial and operational results
Post Your Comments:
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... ... ... In a new case report published today in STEM CELLS Translational Medicine, ... after being treated for breast cancer benefitted from an injection of stem cells derived ... debilitating, frequent side effect of cancer treatment. , Lymphedema refers to the ...
Breaking Biology Technology:
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
Breaking Biology News(10 mins):